{ "run": { "id": "cmnr13uc103zqp6583s318vyv", "region": "US", "assetId": "cmnr13ubc03zmp658knbc5lwk", "ticker": "GILD", "snapshotId": "cmnr13ubj03zop658x7wbbskj", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:49.486Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr13ubj03zop658x7wbbskj", "assetId": "cmnr13ubc03zmp658knbc5lwk", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 141.54, "dayLow": 138.47, "volume": 4916570, "dayHigh": 141.57, "currency": "USD", "prevClose": 138.8, "week52Low": 93.37, "week52High": 157.29 }, "fundamentals": { "pe": 17.9444444444444, "beta": 0.412782327633938, "epsTTM": 6.84, "fcfTTM": 7437000000, "growth": { "epsYoy": 17, "revenueYoy": 0.02396188356402587 }, "sector": "Biological Products, (No Diagnostic Substances)", "margins": { "net": 0.004981975778686865, "gross": 0.2401879379480741, "operating": 0.1648912471140994 }, "website": "http://gilead.com", "industry": "Pharmaceutics", "pegRatio": 0.0105555555555556, "ebitdaTTM": 15139000000, "forwardPe": 14.156862745098, "marketCap": 103200000000, "totalCash": 7564000000, "totalDebt": 27744000000, "debtEquity": 1.22204113993745, "quickRatio": 1.061965631084399, "revenueTTM": 24689000000, "companyName": "GILEAD SCIENCES, INC.", "priceToBook": 3.23424189790299, "currentRatio": 1.552696182172183, "dividendYield": 0.026216764373179, "returnOnAssets": 0.002083933381901971, "returnOnEquity": 0.374840329471876, "analystOpinions": null, "businessSummary": "Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.", "enterpriseValue": 172868560000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 17000, "sharesOutstanding": 1241420528, "enterpriseToEbitda": 11.41875685316071, "analystTargetMedian": null, "enterpriseToRevenue": 7.00184535623152, "operatingCashflowTTM": 10019000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:49.472Z" }, "results": [ { "id": "cmnr13uc303zsp658r4dk6wym", "runId": "cmnr13uc103zqp6583s318vyv", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"GILD\",\"currency\":\"USD\",\"current_price\":141.54,\"target_price_6m\":149.0,\"target_price_12m\":156.0,\"recommendation\":\"BUY\",\"confidence\":0.68,\"thesis_bullets\":[\"Lenacapavir long-acting HIV franchise is a major multi-year growth catalyst\",\"Strong FCF generation (~$7.4B TTM) supports dividend and deleveraging\",\"Forward P/E of ~14x undervalues expected EPS step-up toward $10\",\"Defensive beta (0.41) offers portfolio resilience in volatile markets\",\"Oncology portfolio (Trodelvy, cell therapy) adds diversified upside\"],\"key_drivers\":[{\"driver\":\"Lenacapavir PrEP/treatment launch and global uptake\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biktarvy HIV franchise durability and pricing power\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Oncology revenue ramp (Trodelvy, Yescarta)\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"HCV franchise secular decline (Sovaldi/Harvoni)\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Elevated net debt (~$20B) limits financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Potential US drug pricing reform / IRA negotiation impact\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend yield of ~2.6% provides income floor\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Share buyback program supports EPS accretion\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Lenacapavir uptake below expectations or safety signals emerge\",\"IRA Medicare price negotiation erodes HIV franchise margins\",\"Generic/biosimilar competition accelerates in core HIV products\",\"Large M&A misstep depletes balance sheet without earnings accretion\",\"Oncology competitive landscape intensifies (ADC and cell therapy rivals)\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.40,\"wacc\":0.08,\"terminal_multiple\":14.0},\"scenarios\":{\"bear\":{\"target_price\":118.0,\"prob\":0.20,\"notes\":\"Pipeline setbacks or pricing headwinds compress earnings to ~$7.50 EPS at 15x.\"},\"base\":{\"target_price\":156.0,\"prob\":0.55,\"notes\":\"Steady HIV growth plus lenacapavir ramp drive EPS toward $10; 15.5x multiple.\"},\"bull\":{\"target_price\":182.0,\"prob\":0.25,\"notes\":\"Lenacapavir blockbuster + oncology acceleration push EPS above $11; 16.5x multiple.\"}},\"method_notes\":\"Blended forward P/E and EV/EBITDA valuation. Snapshot net margin (0.5%) appears depressed by one-time charges; normalized operating margin ~40% used. Forward EPS ~$10 anchored on 17% YoY EPS growth continuing with lenacapavir. 12M target $156 implies ~10.2% price return + 2.6% dividend = ~12.8% total return, supporting BUY. Probability-weighted scenario price = $154.9 confirming base case. Sell-side consensus noted but not used as numeric input. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Lenacapavir uptake below expectations or safety signals emerge", "IRA Medicare price negotiation erodes HIV franchise margins", "Generic/biosimilar competition accelerates in core HIV products", "Large M&A misstep depletes balance sheet without earnings accretion", "Oncology competitive landscape intensifies (ADC and cell therapy rivals)" ], "ticker": "GILD", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady HIV growth plus lenacapavir ramp drive EPS toward $10; 15.5x multiple.", "target_price": 156 }, "bear": { "prob": 0.2, "notes": "Pipeline setbacks or pricing headwinds compress earnings to ~$7.50 EPS at 15x.", "target_price": 118 }, "bull": { "prob": 0.25, "notes": "Lenacapavir blockbuster + oncology acceleration push EPS above $11; 16.5x multiple.", "target_price": 182 } }, "confidence": 0.68, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.05, "terminal_multiple": 14, "ebit_margin_target": 0.4 }, "key_drivers": [ { "driver": "Lenacapavir PrEP/treatment launch and global uptake", "impact": "HIGH", "direction": "POS" }, { "driver": "Biktarvy HIV franchise durability and pricing power", "impact": "HIGH", "direction": "POS" }, { "driver": "Oncology revenue ramp (Trodelvy, Yescarta)", "impact": "MED", "direction": "POS" }, { "driver": "HCV franchise secular decline (Sovaldi/Harvoni)", "impact": "MED", "direction": "NEG" }, { "driver": "Elevated net debt (~$20B) limits financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Potential US drug pricing reform / IRA negotiation impact", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield of ~2.6% provides income floor", "impact": "LOW", "direction": "POS" }, { "driver": "Share buyback program supports EPS accretion", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended forward P/E and EV/EBITDA valuation. Snapshot net margin (0.5%) appears depressed by one-time charges; normalized operating margin ~40% used. Forward EPS ~$10 anchored on 17% YoY EPS growth continuing with lenacapavir. 12M target $156 implies ~10.2% price return + 2.6% dividend = ~12.8% total return, supporting BUY. Probability-weighted scenario price = $154.9 confirming base case. Sell-side consensus noted but not used as numeric input. Not investment advice.", "current_price": 141.54, "recommendation": "BUY", "thesis_bullets": [ "Lenacapavir long-acting HIV franchise is a major multi-year growth catalyst", "Strong FCF generation (~$7.4B TTM) supports dividend and deleveraging", "Forward P/E of ~14x undervalues expected EPS step-up toward $10", "Defensive beta (0.41) offers portfolio resilience in volatile markets", "Oncology portfolio (Trodelvy, cell therapy) adds diversified upside" ], "target_price_6m": 149, "target_price_12m": 156 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 39792, "createdAt": "2026-04-09T05:20:49.486Z", "usage": { "inputTokens": 3632, "outputTokens": 1910, "costUsd": 0.06591 } }, { "id": "cmnr13uc303zvp6582bu8zqnu", "runId": "cmnr13uc103zqp6583s318vyv", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Pharma_DCF_Comparables_Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"GILD\",\n \"currency\": \"USD\",\n \"current_price\": 141.54,\n \"target_price_6m\": 144,\n \"target_price_12m\": 149,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Core antiviral franchises provide stable cash flow.\",\n \"EPS growth outpaces revenue due to margin improvements.\",\n \"R&D pipeline critical for long-term growth potential.\",\n \"High debt levels increase financial risk exposure.\",\n \"Low revenue growth limits valuation upside.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"HIV drug sales stability\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Hepatitis C market competition\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"R&D pipeline success in antivirals\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Debt reduction and cost management\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Patent expirations on key drugs\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory approvals for new therapies\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Macroeconomic impact on healthcare spending\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Patent cliffs reducing revenue from legacy products\",\n \"Intense competition in the antiviral drug market\",\n \"Regulatory setbacks for pipeline candidates\",\n \"High debt servicing costs affecting profitability\",\n \"Economic downturn impacting drug pricing and demand\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.17,\n \"wacc\": 0.08,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 140, \"prob\": 0.2, \"notes\": \"Pipeline failures and sales decline pressure margins.\" },\n \"base\": { \"target_price\": 149, \"prob\": 0.6, \"notes\": \"Steady execution with moderate growth and cost control.\" },\n \"bull\": { \"target_price\": 160, \"prob\": 0.2, \"notes\": \"Strong pipeline uptake and significant debt reduction.\" }\n },\n \"method_notes\": \"DCF with assumed 4% revenue CAGR, 17% EBIT margin, 8% WACC, 10x terminal multiple. Target based on forward P/E ~15x. Expected return ~5.3%, hence HOLD. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Pharma_DCF_Comparables_Model", "risks": [ "Patent cliffs reducing revenue from legacy products", "Intense competition in the antiviral drug market", "Regulatory setbacks for pipeline candidates", "High debt servicing costs affecting profitability", "Economic downturn impacting drug pricing and demand" ], "ticker": "GILD", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution with moderate growth and cost control.", "target_price": 149 }, "bear": { "prob": 0.2, "notes": "Pipeline failures and sales decline pressure margins.", "target_price": 140 }, "bull": { "prob": 0.2, "notes": "Strong pipeline uptake and significant debt reduction.", "target_price": 160 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.04, "terminal_multiple": 10, "ebit_margin_target": 0.17 }, "key_drivers": [ { "driver": "HIV drug sales stability", "impact": "HIGH", "direction": "POS" }, { "driver": "Hepatitis C market competition", "impact": "MED", "direction": "NEG" }, { "driver": "R&D pipeline success in antivirals", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt reduction and cost management", "impact": "MED", "direction": "POS" }, { "driver": "Patent expirations on key drugs", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory approvals for new therapies", "impact": "HIGH", "direction": "POS" }, { "driver": "Macroeconomic impact on healthcare spending", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF with assumed 4% revenue CAGR, 17% EBIT margin, 8% WACC, 10x terminal multiple. Target based on forward P/E ~15x. Expected return ~5.3%, hence HOLD. Not investment advice.", "current_price": 141.54, "recommendation": "HOLD", "thesis_bullets": [ "Core antiviral franchises provide stable cash flow.", "EPS growth outpaces revenue due to margin improvements.", "R&D pipeline critical for long-term growth potential.", "High debt levels increase financial risk exposure.", "Low revenue growth limits valuation upside." ], "target_price_6m": 144, "target_price_12m": 149 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 341, "createdAt": "2026-04-09T05:20:49.486Z", "usage": { "inputTokens": 2130, "outputTokens": 3954, "costUsd": 0.002257 } }, { "id": "cmnr13uc303ztp6588485e2pd", "runId": "cmnr13uc103zqp6583s318vyv", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Model Recommendation\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"GILD\",\n \"currency\": \"USD\",\n \"current_price\": 141.54,\n \"target_price_6m\": 143.00,\n \"target_price_12m\": 145.00,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Core HIV franchise remains resilient but faces long-term patent cliff risks.\",\n \"Oncology segment growth is promising but insufficient to offset broader stagnation.\",\n \"Strong free cash flow generation supports a reliable 2.6 percent dividend yield.\",\n \"High debt load of 27.7B limits aggressive M&A flexibility in the near term.\",\n \"Valuation appears full at 14x forward earnings given low single-digit revenue growth.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biktarvy market share\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Trodelvy label expansions\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"HIV patent expirations\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Cell therapy adoption\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt reduction progress\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"HCV market contraction\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Pipeline clinical trial readouts\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Generic competition for key HIV drugs post-loss of exclusivity.\",\n \"Clinical trial failures in the oncology pipeline.\",\n \"Pricing pressures from US drug policy reforms and the IRA.\",\n \"Slower-than-expected integration and ROI from recent acquisitions.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.025,\n \"ebit_margin_target\": 0.45,\n \"wacc\": 0.075,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 115.00,\n \"prob\": 0.25,\n \"notes\": \"Generic erosion accelerates and oncology pipeline fails to deliver expected growth.\"\n },\n \"base\": {\n \"target_price\": 145.00,\n \"prob\": 0.55,\n \"notes\": \"Steady HIV cash flows and moderate oncology growth justify current valuation multiples.\"\n },\n \"bull\": {\n \"target_price\": 175.00,\n \"prob\": 0.20,\n \"notes\": \"Blockbuster pipeline approvals and rapid oncology market penetration drive multiple expansion.\"\n }\n },\n \"method_notes\": \"Blended valuation using 10x EV/EBITDA and 14x Forward P/E. Upside is limited to ~2.4% given slow top-line growth, resulting in a HOLD recommendation. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation", "risks": [ "Generic competition for key HIV drugs post-loss of exclusivity.", "Clinical trial failures in the oncology pipeline.", "Pricing pressures from US drug policy reforms and the IRA.", "Slower-than-expected integration and ROI from recent acquisitions." ], "ticker": "GILD", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady HIV cash flows and moderate oncology growth justify current valuation multiples.", "target_price": 145 }, "bear": { "prob": 0.25, "notes": "Generic erosion accelerates and oncology pipeline fails to deliver expected growth.", "target_price": 115 }, "bull": { "prob": 0.2, "notes": "Blockbuster pipeline approvals and rapid oncology market penetration drive multiple expansion.", "target_price": 175 } }, "confidence": 0.65, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.025, "terminal_multiple": 10, "ebit_margin_target": 0.45 }, "key_drivers": [ { "driver": "Biktarvy market share", "impact": "HIGH", "direction": "POS" }, { "driver": "Trodelvy label expansions", "impact": "MED", "direction": "POS" }, { "driver": "HIV patent expirations", "impact": "HIGH", "direction": "NEG" }, { "driver": "Cell therapy adoption", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction progress", "impact": "MED", "direction": "POS" }, { "driver": "HCV market contraction", "impact": "MED", "direction": "NEG" }, { "driver": "Pipeline clinical trial readouts", "impact": "HIGH", "direction": "POS" } ], "method_notes": "Blended valuation using 10x EV/EBITDA and 14x Forward P/E. Upside is limited to ~2.4% given slow top-line growth, resulting in a HOLD recommendation. Not investment advice.", "current_price": 141.54, "recommendation": "HOLD", "thesis_bullets": [ "Core HIV franchise remains resilient but faces long-term patent cliff risks.", "Oncology segment growth is promising but insufficient to offset broader stagnation.", "Strong free cash flow generation supports a reliable 2.6 percent dividend yield.", "High debt load of 27.7B limits aggressive M&A flexibility in the near term.", "Valuation appears full at 14x forward earnings given low single-digit revenue growth." ], "target_price_6m": 143, "target_price_12m": 145 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 25017, "createdAt": "2026-04-09T05:20:49.486Z", "usage": { "inputTokens": 2488, "outputTokens": 852, "costUsd": 0.0152 } }, { "id": "cmnr13uc303zrp658pjkl5mgh", "runId": "cmnr13uc103zqp6583s318vyv", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"GILD\",\"currency\":\"USD\",\"current_price\":141.54,\"target_price_6m\":146,\"target_price_12m\":149,\"recommendation\":\"HOLD\",\"confidence\":0.64,\"thesis_bullets\":[\"HIV portfolio remains durable and funds dividends, R&D, and bolt-on deals.\",\"Oncology pipeline offers upside, but execution and label expansion remain uncertain.\",\"Forward P/E near mid-teens looks fair for low-single-digit top-line growth.\",\"Strong cash flow offsets leverage, though debt limits major capital flexibility.\",\"Risk-reward appears balanced after strong share performance and modest 12M upside.\"],\"key_drivers\":[{\"driver\":\"HIV franchise durability\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Long-acting HIV innovation uptake\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Oncology portfolio growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin normalization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction pace\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pipeline trial outcomes\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Patent/exclusivity erosion\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Drug pricing pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"HIV competition or reimbursement pressure\",\"Oncology trials disappoint or uptake stalls\",\"Acquisition integration or write-downs recur\",\"Drug-pricing reform compresses margins\",\"Higher leverage reduces flexibility\"],\"assumptions\":{\"revenue_cagr_3y\":0.045,\"ebit_margin_target\":0.31,\"wacc\":0.085,\"terminal_multiple\":12.5},\"scenarios\":{\"bear\":{\"target_price\":118,\"prob\":0.25,\"notes\":\"HIV growth slows and oncology underdelivers, compressing valuation.\"},\"base\":{\"target_price\":149,\"prob\":0.5,\"notes\":\"Core HIV cash flows hold and oncology grows steadily.\"},\"bull\":{\"target_price\":171,\"prob\":0.25,\"notes\":\"Long-acting HIV and oncology outperform, supporting a rerating.\"}},\"method_notes\":\"Snapshot quote/fundamentals used as authoritative inputs. Valuation blends normalized earnings/FCF with a 12.5x terminal EBIT anchor and 8.5% WACC; no sell-side price targets used. HOLD fits ~5% 12M upside, below BUY threshold, with mixed growth and leverage signals; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation v2", "risks": [ "HIV competition or reimbursement pressure", "Oncology trials disappoint or uptake stalls", "Acquisition integration or write-downs recur", "Drug-pricing reform compresses margins", "Higher leverage reduces flexibility" ], "ticker": "GILD", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Core HIV cash flows hold and oncology grows steadily.", "target_price": 149 }, "bear": { "prob": 0.25, "notes": "HIV growth slows and oncology underdelivers, compressing valuation.", "target_price": 118 }, "bull": { "prob": 0.25, "notes": "Long-acting HIV and oncology outperform, supporting a rerating.", "target_price": 171 } }, "confidence": 0.64, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.045, "terminal_multiple": 12.5, "ebit_margin_target": 0.31 }, "key_drivers": [ { "driver": "HIV franchise durability", "impact": "HIGH", "direction": "POS" }, { "driver": "Long-acting HIV innovation uptake", "impact": "HIGH", "direction": "POS" }, { "driver": "Oncology portfolio growth", "impact": "MED", "direction": "POS" }, { "driver": "Margin normalization", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction pace", "impact": "MED", "direction": "POS" }, { "driver": "Pipeline trial outcomes", "impact": "HIGH", "direction": "POS" }, { "driver": "Patent/exclusivity erosion", "impact": "MED", "direction": "NEG" }, { "driver": "Drug pricing pressure", "impact": "MED", "direction": "NEG" } ], "method_notes": "Snapshot quote/fundamentals used as authoritative inputs. Valuation blends normalized earnings/FCF with a 12.5x terminal EBIT anchor and 8.5% WACC; no sell-side price targets used. HOLD fits ~5% 12M upside, below BUY threshold, with mixed growth and leverage signals; not investment advice.", "current_price": 141.54, "recommendation": "HOLD", "thesis_bullets": [ "HIV portfolio remains durable and funds dividends, R&D, and bolt-on deals.", "Oncology pipeline offers upside, but execution and label expansion remain uncertain.", "Forward P/E near mid-teens looks fair for low-single-digit top-line growth.", "Strong cash flow offsets leverage, though debt limits major capital flexibility.", "Risk-reward appears balanced after strong share performance and modest 12M upside." ], "target_price_6m": 146, "target_price_12m": 149 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_05b85688bbadfc1f0069d7596278008196a1b5cad4e7e5abc6", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 45579, "createdAt": "2026-04-09T05:20:49.486Z", "usage": { "inputTokens": 2404, "outputTokens": 2429, "costUsd": 0.038213 } }, { "id": "cmnr13uc303zup658eo3atfe6", "runId": "cmnr13uc103zqp6583s318vyv", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"GILD Fundamental DCF Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"GILD\",\n \"currency\": \"USD\",\n \"current_price\": 141.54,\n \"target_price_6m\": 152,\n \"target_price_12m\": 160,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Stable HIV franchise anchors consistent cash flows\",\n \"Oncology expansion via Kite and Trodelvy progressing\",\n \"Strong FCF supports dividends and pipeline investment\",\n \"HCV sales decline offsets overall revenue growth\",\n \"Forward valuation attractive versus cash flow yield\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"HIV franchise durability\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Oncology portfolio uptake\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"HCV revenue erosion\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"New drug pipeline success\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"M&A integration execution\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Drug pricing pressures\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Robust operating cash flow\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Patent expiration timeline\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Patent cliffs on key HIV drugs\",\n \"Clinical trial failures in oncology\",\n \"Intense competition in antivirals\",\n \"Regulatory hurdles for new approvals\",\n \"Overpayment risk on acquisitions\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.32,\n \"wacc\": 0.085,\n \"terminal_multiple\": 14\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 118,\n \"prob\": 0.3,\n \"notes\": \"Pipeline misses and faster HCV decline compress multiples.\"\n },\n \"base\": {\n \"target_price\": 160,\n \"prob\": 0.5,\n \"notes\": \"Steady HIV sales and gradual oncology contribution.\"\n },\n \"bull\": {\n \"target_price\": 195,\n \"prob\": 0.2,\n \"notes\": \"Accelerated new launches and strong oncology adoption.\"\n }\n },\n \"method_notes\": \"Valuation uses DCF with stated assumptions plus sum-of-parts for oncology. 13% expected 12M return supports BUY per rubric; mixed growth offset by cash flow. Consensus targets not used as inputs. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "GILD Fundamental DCF Model", "risks": [ "Patent cliffs on key HIV drugs", "Clinical trial failures in oncology", "Intense competition in antivirals", "Regulatory hurdles for new approvals", "Overpayment risk on acquisitions" ], "ticker": "GILD", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady HIV sales and gradual oncology contribution.", "target_price": 160 }, "bear": { "prob": 0.3, "notes": "Pipeline misses and faster HCV decline compress multiples.", "target_price": 118 }, "bull": { "prob": 0.2, "notes": "Accelerated new launches and strong oncology adoption.", "target_price": 195 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 14, "ebit_margin_target": 0.32 }, "key_drivers": [ { "driver": "HIV franchise durability", "impact": "HIGH", "direction": "POS" }, { "driver": "Oncology portfolio uptake", "impact": "HIGH", "direction": "POS" }, { "driver": "HCV revenue erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "New drug pipeline success", "impact": "MED", "direction": "POS" }, { "driver": "M&A integration execution", "impact": "MED", "direction": "POS" }, { "driver": "Drug pricing pressures", "impact": "MED", "direction": "NEG" }, { "driver": "Robust operating cash flow", "impact": "HIGH", "direction": "POS" }, { "driver": "Patent expiration timeline", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Valuation uses DCF with stated assumptions plus sum-of-parts for oncology. 13% expected 12M return supports BUY per rubric; mixed growth offset by cash flow. Consensus targets not used as inputs. Not investment advice.", "current_price": 141.54, "recommendation": "BUY", "thesis_bullets": [ "Stable HIV franchise anchors consistent cash flows", "Oncology expansion via Kite and Trodelvy progressing", "Strong FCF supports dividends and pipeline investment", "HCV sales decline offsets overall revenue growth", "Forward valuation attractive versus cash flow yield" ], "target_price_6m": 152, "target_price_12m": 160 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "418f969a-fe3e-9cf2-ad6e-556bdd39db31", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 18638, "createdAt": "2026-04-09T05:20:49.486Z", "usage": { "inputTokens": 2738, "outputTokens": 3556, "costUsd": 0.061554 } } ] } }